Non-invasive detection methods based on liquid biopsy (such as circulating tumor cells) should be developed to monitor the dynamic changes in SLFN11 expression during the treatment in real time, especially the downward trend of SLFN11 expression after chemotherapy or treatment with PARP inhibitors. This evidence concerns the gene PARP1 and neoplasm.